Welcome to our dedicated page for Satellos Bioscience SEC filings (Ticker: MSLE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Satellos Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Satellos Bioscience's regulatory disclosures and financial reporting.
Satellos Bioscience Inc. reports the results of its Annual Meeting of Shareholders held on June 17, 2026. Shareholders present or represented by proxy accounted for 55.3% of the issued and outstanding common shares, providing a solid participation base for governance decisions.
All director nominees listed in the May 14, 2026 management information circular were elected, with most receiving over 99% of votes cast in their favor. Satellos shareholders also approved the re-appointment of PricewaterhouseCoopers LLP as the Company’s auditors.
The filing also reiterates that Satellos is a clinical-stage drug development company advancing SAT-3247 in two Phase II trials for degenerative muscle diseases, including Duchenne muscular dystrophy, and includes standard forward-looking statement disclosures outlining development and regulatory risks.
Satellos Bioscience Inc. reported the results of its annual shareholder meeting held virtually on June 17, 2026. Shareholders elected all nominated directors, with support levels generally very high.
Turnout was solid, with approximately 55.33% of issued and outstanding shares represented in person or by proxy. Most directors received about 99% of votes cast in favour. Stephanie Brown received 92.22% support, and Iris Loew-Friedrich received 83.76% support, while all other nominees were supported by at least 99.69% of votes cast.
Satellos Bioscience Inc. announced that its management team will present at two investor conferences in June. The company will speak at the Jefferies Global Healthcare Conference on June 4, 2026 at 11:05 a.m. in New York, and at the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026 at 10:15 a.m. in Miami. Presentations will be available via live webcast on Satellos’ investor relations site, with replays afterward, and management will hold one-on-one meetings with investors. Satellos is a clinical-stage drug developer advancing SAT-3247, an orally administered small molecule targeting AAK1, in two Phase II trials for Duchenne muscular dystrophy, one in pediatric patients (BASECAMP) and one in adults (TRAILHEAD).
Satellos Bioscience Inc. is calling a virtual-only annual general meeting of shareholders on June 17, 2026 at 1:00 p.m. Toronto time to review 2025 financial statements, elect directors and appoint auditors. Only shareholders of record as of May 12, 2026 may vote.
The circular explains detailed proxy and voting procedures for registered and non-registered shareholders, including the need for control numbers and invite codes to vote online. Management recommends voting in favour of all resolutions, including the reappointment of PricewaterhouseCoopers LLP as auditor.
The filing also outlines 2025 compensation for key executives and directors, stock option and RSU awards, and the structure of Satellos’ Equity Incentive Plan. That plan can cover up to 3,124,679 shares, with 2,766,563 awards outstanding and a 2025 burn rate of 7.9% of outstanding shares.
Satellos Bioscience Inc. ownership disclosure: three reporting persons state combined beneficial ownership of 1,137,041 ordinary shares, representing 7.35% of the class.
The filing attributes the 7.35% figure to a calculation using 15,458,903 ordinary shares outstanding as of February 5, 2026 and 3,641 common shares issuable upon exercise of options owned by the reporting persons. Ownership breaks down into 126,874 shares with sole voting/dispositive power and 1,010,167 shares with shared voting/dispositive power, held across individuals and affiliated entities named in the filing.
Satellos Bioscience Inc. reported a wider net loss of $9,768 for the three months ended March 31, 2026, compared with $6,141 a year earlier, as it ramped spending on clinical programs for its lead DMD candidate SAT-3247. Research and development expenses rose to $7,310 from $4,542, driven mainly by the BASECAMP and TRAILHEAD Phase 2 studies and related manufacturing work, while general and administrative costs increased to $2,733 from $1,937 due to higher professional and operating expenses tied to its Nasdaq listing and growth. A February 2026 equity offering of 5,168,019 Common Shares and 495,049 pre-funded warrants generated net proceeds of $51,901, lifting cash and short-term investments to $69,911 at March 31, 2026 from $27,710 at year-end and supporting management’s view that available cash provides runway through 2027. BASECAMP, a 51-patient pediatric Phase 2 trial, is enrolling across 11 active sites and remains on track to complete enrollment in Q3 2026, while the adult TRAILHEAD Phase 2 study has been initiated in the United States, with participants from the earlier Phase 1b trial already re-started on SAT-3247.
Satellos Bioscience Inc. ownership update: Qiming U.S. Healthcare Fund III, L.P. reports beneficial ownership of 1,725,247 common shares as of March 31, 2026, representing 8.3% of the class. The filing states 20,831,190 Shares outstanding as of March 27, 2026.
The report identifies Qiming U.S. Healthcare GP III, LLC as the general partner and names Mark McDade and Gary Rieschel as managing partners who may be deemed to beneficially own the same shares through shared voting and dispositive power.
Satellos Bioscience Inc., a clinical-stage biotechnology company focused on degenerative muscle diseases, will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. Co-founder and CEO Frank Gleeson will give a presentation on April 21 at 11:30 a.m., with a live webcast and replay available via the Investors section of the company’s website.
The company is developing SAT-3247, an orally administered small molecule therapy aimed at restoring muscle repair and regeneration. SAT-3247 is being studied as a potential disease-modifying treatment for Duchenne muscular dystrophy in two Phase II trials, BASECAMP in pediatric patients and TRAILHEAD in adults.
Satellos Bioscience Inc. filed its Annual Report on Form 40-F disclosing incorporated exhibits including an Annual Information Form, audited consolidated financial statements for the years ended December 31, 2025 and 2024, and an MD&A.
The filing names PricewaterhouseCoopers LLP as auditor and states the company is an emerging growth company. Shares outstanding were 15,458,903 Common Shares as of the close of the period covered by the annual report. The filing includes SOX certifications and references disclosure controls and internal control information in the MD&A.
Satellos Bioscience Inc. reported interim clinical and biomarker results for its oral drug candidate SAT-3247 in Duchenne muscular dystrophy at the 2026 MDA Clinical & Scientific Conference.
In the ongoing Phase 2 TRAILHEAD study in adults with Duchenne, investigators observed continued improvement in handgrip strength and overall stability of elbow and shoulder strength at Day 56 after re-enrollment, with greater strength gains in participants who started with more muscle mass.
A 28-day Phase 1a/b study (CL-101) showed consistent changes across more than 11,000 serum proteins, including reductions in established Duchenne biomarkers within two weeks of SAT-3247 treatment. Satellos also highlighted development of a regenerative index tool now used in the pediatric BASECAMP trial and preclinical data in a mouse model of facioscapulohumeral muscular dystrophy, where 12-week dosing significantly enhanced muscle strength, suggesting broader potential beyond Duchenne.